 Drug Interactions
"Drug Interactions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
| Descriptor ID |
D004347
|
| MeSH Number(s) |
G07.690.812.240 G07.700.680.240
|
| Concept/Terms |
Drug Interactions- Drug Interactions
- Drug Interaction
- Interaction, Drug
- Interactions, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Interactions".
Below are MeSH descriptors whose meaning is more specific than "Drug Interactions".
This graph shows the total number of publications written about "Drug Interactions" by people in this website by year, and whether "Drug Interactions" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 0 | 1 | 1 | | 1983 | 0 | 2 | 2 | | 1984 | 0 | 1 | 1 | | 1985 | 0 | 1 | 1 | | 1986 | 0 | 2 | 2 | | 1987 | 0 | 1 | 1 | | 1990 | 0 | 3 | 3 | | 1991 | 0 | 2 | 2 | | 1993 | 0 | 2 | 2 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1998 | 0 | 5 | 5 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 3 | 3 | | 2006 | 0 | 6 | 6 | | 2007 | 0 | 3 | 3 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 4 | 5 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Interactions" by people in Profiles.
-
Navis A, Dallah I, Mabeta C, Musukuma K, Siddiqi OK, Bositis CM, Koralnik IJ, Gelbard HA, Theodore WH, Okulicz JF, Johnson BA, Sikazwe I, Bearden DR, Birbeck GL. Evaluating the impact of antiretroviral and antiseizure medication interactions on treatment effectiveness among outpatient clinic attendees with HIV in Zambia. Epilepsia. 2020 12; 61(12):2705-2711.
-
Speed V, Patel RK, Byrne R, Roberts LN, Arya R. A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic. Thromb Res. 2020 08; 192:73-74.
-
Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. JAMA. 2017 09 26; 318(12):1115-1124.
-
Conn VS, Ruppar TM, Enriquez M, Cooper PS. Patient-Centered Outcomes of Medication Adherence Interventions: Systematic Review and Meta-Analysis. Value Health. 2016 Mar-Apr; 19(2):277-85.
-
Arif SA, D'Souza J, Gil M, Gim S. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. Am J Health Syst Pharm. 2015 Oct 01; 72(19):1615-22.
-
Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v.
-
Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305.
-
Doukky R, Morales Demori R, Jain S, Kiriakos R, Mwansa V, Calvin JE. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial". J Nucl Cardiol. 2012 Jun; 19(3):448-57.
-
Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, Goldstein EJ. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 2012 Jan; 39(1):11-5.
-
Arif SA, Poon H. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin Ther. 2011 Aug; 33(8):993-1004.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|